Ayushman Expansion and Pediatric Drug Safety Restrictions

This report covers developments in Ayushman Bharat, pharmaceutical regulation, and digital health from August 18, 2026, to August 25, 2026. Key findings include the launch of distinct health cards for senior citizens, significant restrictions on pediatric drug combinations, and the inclusion of the European Union in medical device clinical trial waivers.

Key Statistics

Weekly Executive Summary

• The National Health Authority (NHA) surpassed the 40-crore milestone for PM-JAY cards while intensifying anti-fraud measures using AI-driven claim monitoring.
• The Ministry of Health and Family Welfare (MoHFW) issued a notification prohibiting specific Fixed Dose Combinations (FDCs) for children under four years of age to prevent toxicity.
• Significant amendments were made to the Medical Devices Rules, 2017, to streamline clinical investigation waivers for EU-approved devices and standardize laboratory testing fees.

Deep Dive: Key Developments

Rollout of Senior Citizen…